ALNY News and Press, Alnylam Pharmaceuticals Inc. From 11/23/21

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Evercore ISI 4 th Annual HealthCONx Conference on Tuesday, November 30, 20...

Electric vehicle companies remained prominent in Monday's midday trading. Tesla (NASDAQ:TSLA) gained ground on an update of its Model S Plaid launch in China, while Rivian (NASDAQ:RIVN) plunged on news that a joint project with Ford (NYSE:F) has been canceled. Elsewhere, Alnylam Pharmaceutica...

Shares of Alnylam Pharmaceuticals (ALNY +7.0%) are up in trading today following upgrades from Goldman Sachs and RBC Capital Markets. Goldman upgraded the stock to buy from neutral and set a $273 price target (~51% upside). RBC upgraded to outperform with a $225 price target (~24% upside). Go...

Alnylam Pharmaceuticals (NASDAQ:ALNY) says it plans to launch vutrisiran for hATTR amyloidosis in the U.S. early next year following anticipated FDA approval. The biotech anticipates approval of the drug in Europe in mid-2022. Alnylam will begin a phase 3 study of the drug in Stargardt D...

− Introduces New Near-Term Opportunity for Vutrisiran in Stargardt Disease, Expected to Enter Phase 3 Development in Late 2022 – – Adds New Preclinical Cardiovascular Disease Programs, GEMINI-CVR and “Gene X,” with Highly Transfor...

Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda. RNA interference is...

Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis as investor push for the drugmaker to make an acquisition. Alnylam, with a market cap of more than $20B could be a possible acquisition candidate, according to a Bloomberg report, which cited people familiar. Novarti...

Novo Nordisk (NYSE:NVO) has signed an agreement with Dicerna Pharmaceuticals (NASDAQ:DRNA) under which it will acquire Dicerna for $38.25 per share in cash. The purchase consideration indicating a premium of 80% to Dicerna’s closing price on Nov. 17 implies a total equity value of $3.3...

– Single Doses of Investigational Zilebesiran Resulted in Sustained Serum Angiotensinogen and Blood Pressure Reductions Through Six Months, Supporting Quarterly and Potentially Biannual Dosing – – Blood Pressure Response to Low-Salt Intake under the Peak P...

Alnylam Pharmaceuticals (NASDAQ:ALNY) announces the initiation of a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), which is being developed as a treatment for hypertension. The trial will evaluate the efficacy and safety of zilebesira...